secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0000950170-23-053987
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma reports Q3 2023 net loss of $1.4M; cash $38.5M sufficient through end of 2024
--------------------------------------------------------------------------------

- Net loss of $1.4M ($0.10/share) vs $2.3M ($0.16/share) in Q3 2022; operating expenses down to $2.0M from $2.6M.
- Cash and equivalents $38.5M at Sep 30, 2023 (down from $42.4M at Dec 31, 2022); funding runway through end of 2024.
- R&D expenses fell to $0.3M from $1.0M YoY due to prior 67% workforce reduction (12 employees) in July 2022.
- Strategic review process with Ladenburg Thalmann continues; no defined timeline and may not result in a transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/0000950170-23-053987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/abio-20231018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer